Treat a switch as a change of product, not a change of supplier. Brand tirzepatide is FDA-approved, supplied at fixed strengths in single-dose presentations. Compounded tirzepatide is not FDA-approved, is not reviewed by FDA for safety, effectiveness or quality, and its concentration is set by the preparing pharmacy. Numbers printed on one label do not carry across to the other.
What actually changes at the moment of a switch
Four things move at once, and only one of them is the price. The regulatory category changes, which changes what is known about the product. The concentration may change, since a compounded strength and fill volume are decided locally. The delivery format often changes, because approved presentations are single-dose devices while compounded supply frequently arrives as a vial with syringes. The accountability chain changes, since the manufacturer, the dispensing pharmacy and the prescriber may all be different parties before and after.
That last point is easy to skip and expensive to skip. A patient who cannot name who prepared the current supply has no way to answer the first question a new prescriber will ask.
Moving from a compounded preparation to the approved product
This direction is usually driven by coverage becoming available, by a program closing, or by a preference for a reviewed product. The obstacle is rarely clinical and usually documentary. A prescriber writing for the approved brand is writing against a labeled indication, so the record needs to show which condition is being treated: type 2 diabetes for the diabetes-labeled brand, and long-term weight reduction or moderate to severe obstructive sleep apnea with obesity for the weight-labeled one.
Useful requests to make before the appointment are the treatment history in writing, including how long the compounded product has been used and at what stated strength, the name and license state of the dispensing pharmacy, and any documented response such as weight trend, glycated hemoglobin values or a sleep study. Practices differ in how readily they hand that over. Cash-pay programs such as Henry Meds and FormBlends publish the terms of their programs up front, which makes the request straightforward to frame, while a seller that never named a pharmacy will not be able to produce a usable record at all.
Moving from the approved product to a compounded preparation
The common driver here is cost or a coverage lapse, and it is worth saying plainly that this is a real pressure rather than a failure of judgment. It is also the direction that deserves the most scrutiny, because it trades a reviewed product for one that has not been reviewed. FDA’s framing is that compounded medication is appropriate when a patient’s medical need cannot be met by an approved drug, or when the approved drug is not commercially available, so the first question is whether the approved route has genuinely been exhausted, including manufacturer cash terms.
If the answer is yes, the checks that follow are about the specific preparation rather than the category. The stated concentration and how the dose is measured. The name and license state of the pharmacy, and whether it operates as a state-licensed pharmacy under section 503A or as a registered outsourcing facility under section 503B, which carries current good manufacturing practice requirements and FDA inspection on a risk-based schedule. The beyond-use date. Whether the product ships refrigerated, since FDA has received complaints about compounded GLP-1 products arriving warm or with inadequate ice packs and recommends against using them.
When that route is chosen, the choice is rarely between two names but among several. Approved supply comes through a plan or through LillyDirect, while supervised cash programs such as HealthRX, Henry Meds, Ro, and Hims and Hers publish their own terms for compounded tirzepatide. What separates them is not the peptide but the record each keeps: the stated strength, the named pharmacy, and the clinician who signs the prescription.
| Question to ask | Why it matters | What a complete answer sounds like |
|---|---|---|
| What is the stated concentration | Dose measurement depends on it | A specific figure, in writing, on the label |
| Who prepares and dispenses it | Determines the oversight regime | A named pharmacy and its license state |
| How is my dose determined at the switch | Label numbers do not transfer | The prescriber decides, not a conversion chart |
| What happens if I react badly | Follow-up access differs by program | A named clinician and a stated response time |
| Will there be a gap in supply | Interruption affects maintenance | A shipping date confirmed before the last dose |
| What records will I be given | Needed by the next prescriber | Written treatment history on request |
Why the dose question has to go to the prescriber
There is no reliable arithmetic that converts a compounded regimen into an approved one or the reverse, because the starting information differs. The approved labels define strengths and an escalation interval that were studied. A compounded preparation may be more or less concentrated than the assumption behind those numbers, and FDA has received adverse event reports that may relate to patients being prescribed compounded semaglutide or tirzepatide at doses beyond what appears on the approved label, whether through more product per dose, more frequent dosing, or faster escalation. That is the specific failure mode a transition invites, and it is the reason the dose decision belongs with a clinician who knows both sides of the switch.
Continuity matters more than the switch itself
Both routes treat a chronic condition, and stopping changes the result. The SURMOUNT-4 randomized withdrawal trial ran a 36-week open-label lead-in before randomizing participants to continue tirzepatide or move to placebo for 52 weeks, and it measured how much of the earlier reduction was maintained. A transition that leaves a supply gap is a small unplanned version of that experiment. Confirming the next shipment date before the current supply runs out does more for the outcome than optimizing which tier the medication comes from.
Frequently asked questions
Can a pharmacy convert my compounded dose to a brand dose?
No, and a pharmacy should not be asked to. Conversion depends on the concentration and preparation of the product being left behind, information that is not standardized across compounders. The prescriber makes that decision using the treatment history and the labeled escalation approach for the approved product.
Do I need to stop one before starting the other?
The approved labeling states that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended, so overlapping two supplies is not a way to smooth a transition. Timing the changeover so that only one product is in use belongs in the prescriber conversation.
What if my compounded supplier will not name the pharmacy?
Treat that as the answer. FDA advises obtaining a prescription and filling it at a state-licensed pharmacy, and it has documented fraudulent compounded products carrying labels that name pharmacies that do not exist or that did not prepare the product. A supplier that cannot be identified also cannot be verified or held accountable.
Will a new prescriber accept my compounded treatment history?
Usually as context rather than as proof. Documented weight, laboratory values and dates carry weight because they are observations about the patient. A stated strength from a preparation that was never independently verified carries less, which is why the clinical record matters more than the product record at a switch.
